Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma 1Recurrence 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 4Cytoreduction Surgical Procedures 4Cisplatin 3Oxaliplatin 2Leucovorin 2Fluorouracil 2volociximab 1vandetanib 1pembrolizumab 1pasireotide 1birinapant 1alvimopan 1Therapeutic Irrigation 1Surgical Procedures, Operative 1Saline Waters 1Paclitaxel 1Indocyanine Green 1Folfox protocol 1Docetaxel 1Chemotherapy, Adjuvant 1Cetuximab 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Peritoneal Neoplasms × birinapant × Clear all
NCT01681368 2017-05-30

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
11 enrolled 19 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡